Beta Bionics, Inc. (NASDAQ: BBNX) Stock Competitors & Peer Comparison
See BBNX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BBNX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BBNX | $16.52 | -2.54% | 743.2M | -8.98 | -$1.84 | N/A |
| ABT | $110.46 | -0.05% | 191.1B | 21.20 | $5.21 | +2.29% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $101.59 | -1.17% | 130B | 18.38 | $5.53 | +2.82% |
| SYK | $324.29 | -0.44% | 123.4B | 24.21 | $13.39 | +1.09% |
| BSX | $44.70 | +1.54% | 64.8B | 14.42 | $3.10 | N/A |
| EW | $104.01 | -0.67% | 60B | 38.53 | $2.70 | N/A |
| GEHC | $83.65 | -0.45% | 37.8B | 17.07 | $4.90 | +0.17% |
| DXCM | $79.92 | -1.42% | 29.8B | 31.34 | $2.55 | N/A |
| PHG | $30.41 | -1.23% | 29.7B | 17.37 | $1.75 | +3.26% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
BBNX vs ABT Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, ABT has a market cap of 191.1B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while ABT trades at $110.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas ABT's P/E ratio is 21.20. In terms of profitability, BBNX's ROE is -0.27%, compared to ABT's ROE of +0.09%. Regarding short-term risk, BBNX is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
BBNX vs BSX-PA Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, BBNX's ROE is -0.27%, compared to BSX-PA's ROE of +0.14%. Regarding short-term risk, BBNX is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check BSX-PA's competition here
Medtronic Plc (NYSE: MDT)
BBNX vs MDT Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, MDT has a market cap of 130B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while MDT trades at $101.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas MDT's P/E ratio is 18.38. In terms of profitability, BBNX's ROE is -0.27%, compared to MDT's ROE of +0.11%. Regarding short-term risk, BBNX is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
BBNX vs SYK Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, SYK has a market cap of 123.4B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while SYK trades at $324.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas SYK's P/E ratio is 24.21. In terms of profitability, BBNX's ROE is -0.27%, compared to SYK's ROE of +0.16%. Regarding short-term risk, BBNX is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
BBNX vs BSX Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, BSX has a market cap of 64.8B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while BSX trades at $44.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas BSX's P/E ratio is 14.42. In terms of profitability, BBNX's ROE is -0.27%, compared to BSX's ROE of +0.14%. Regarding short-term risk, BBNX is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
BBNX vs EW Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, EW has a market cap of 60B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while EW trades at $104.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas EW's P/E ratio is 38.53. In terms of profitability, BBNX's ROE is -0.27%, compared to EW's ROE of +0.10%. Regarding short-term risk, BBNX is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check EW's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
BBNX vs GEHC Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, GEHC has a market cap of 37.8B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while GEHC trades at $83.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas GEHC's P/E ratio is 17.07. In terms of profitability, BBNX's ROE is -0.27%, compared to GEHC's ROE of +0.20%. Regarding short-term risk, BBNX is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check GEHC's competition here
DexCom, Inc. (NASDAQ: DXCM)
BBNX vs DXCM Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, DXCM has a market cap of 29.8B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while DXCM trades at $79.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas DXCM's P/E ratio is 31.34. In terms of profitability, BBNX's ROE is -0.27%, compared to DXCM's ROE of +0.37%. Regarding short-term risk, BBNX is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check DXCM's competition here
Koninklijke Philips N.V. (NYSE: PHG)
BBNX vs PHG Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, PHG has a market cap of 29.7B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while PHG trades at $30.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas PHG's P/E ratio is 17.37. In terms of profitability, BBNX's ROE is -0.27%, compared to PHG's ROE of +0.08%. Regarding short-term risk, BBNX is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
BBNX vs ZBH Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, ZBH has a market cap of 20.5B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while ZBH trades at $107.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas ZBH's P/E ratio is 12.66. In terms of profitability, BBNX's ROE is -0.27%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, BBNX is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
BBNX vs ABMD Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas ABMD's P/E ratio is 65.36. In terms of profitability, BBNX's ROE is -0.27%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, BBNX is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check ABMD's competition here
Glaukos Corporation (NYSE: GKOS)
BBNX vs GKOS Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, GKOS has a market cap of 14B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while GKOS trades at $236.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas GKOS's P/E ratio is -274.57. In terms of profitability, BBNX's ROE is -0.27%, compared to GKOS's ROE of -0.25%. Regarding short-term risk, BBNX is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check GKOS's competition here
Smith & Nephew plc (NYSE: SNN)
BBNX vs SNN Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, SNN has a market cap of 13.3B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while SNN trades at $30.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas SNN's P/E ratio is 20.88. In terms of profitability, BBNX's ROE is -0.27%, compared to SNN's ROE of +0.12%. Regarding short-term risk, BBNX is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check SNN's competition here
Penumbra, Inc. (NYSE: PEN)
BBNX vs PEN Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, PEN has a market cap of 12.7B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while PEN trades at $321.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas PEN's P/E ratio is 83.95. In terms of profitability, BBNX's ROE is -0.27%, compared to PEN's ROE of +0.10%. Regarding short-term risk, BBNX is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
BBNX vs SWAV Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas SWAV's P/E ratio is 78.76. In terms of profitability, BBNX's ROE is -0.27%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, BBNX is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check SWAV's competition here
Align Technology, Inc. (NASDAQ: ALGN)
BBNX vs ALGN Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, ALGN has a market cap of 12.4B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while ALGN trades at $174.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas ALGN's P/E ratio is 15.89. In terms of profitability, BBNX's ROE is -0.27%, compared to ALGN's ROE of +0.12%. Regarding short-term risk, BBNX is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check ALGN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
BBNX vs BIO-B Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, BIO-B has a market cap of 10.4B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while BIO-B trades at $389.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas BIO-B's P/E ratio is -68.67. In terms of profitability, BBNX's ROE is -0.27%, compared to BIO-B's ROE of +0.14%. Regarding short-term risk, BBNX is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check BIO-B's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
BBNX vs BIO Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, BIO has a market cap of 10.4B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while BIO trades at $386.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas BIO's P/E ratio is 41.73. In terms of profitability, BBNX's ROE is -0.27%, compared to BIO's ROE of +0.14%. Regarding short-term risk, BBNX is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check BIO's competition here
Insulet Corp. (NASDAQ: PODD)
BBNX vs PODD Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, PODD has a market cap of 10.3B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while PODD trades at $148.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas PODD's P/E ratio is 25.22. In terms of profitability, BBNX's ROE is -0.27%, compared to PODD's ROE of +0.29%. Regarding short-term risk, BBNX is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check PODD's competition here
Globus Medical, Inc. (NYSE: GMED)
BBNX vs GMED Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, GMED has a market cap of 10.1B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while GMED trades at $75.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas GMED's P/E ratio is 16.94. In terms of profitability, BBNX's ROE is -0.27%, compared to GMED's ROE of +0.12%. Regarding short-term risk, BBNX is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check GMED's competition here
Bruker Corporation (NASDAQ: BRKRP)
BBNX vs BRKRP Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, BRKRP has a market cap of 9.5B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while BRKRP trades at $455.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas BRKRP's P/E ratio is 247.38. In terms of profitability, BBNX's ROE is -0.27%, compared to BRKRP's ROE of -0.05%. Regarding short-term risk, BBNX is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check BRKRP's competition here
Bruker Corporation (NASDAQ: BRKR)
BBNX vs BRKR Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, BRKR has a market cap of 9.5B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while BRKR trades at $62.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas BRKR's P/E ratio is 31.28. In terms of profitability, BBNX's ROE is -0.27%, compared to BRKR's ROE of -0.05%. Regarding short-term risk, BBNX is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check BRKR's competition here
Masimo Corporation (NASDAQ: MASI)
BBNX vs MASI Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas MASI's P/E ratio is 44.43. In terms of profitability, BBNX's ROE is -0.27%, compared to MASI's ROE of +0.09%. Regarding short-term risk, BBNX is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check MASI's competition here
Haemonetics Corporation (NYSE: HAE)
BBNX vs HAE Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, HAE has a market cap of 5.6B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while HAE trades at $122.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas HAE's P/E ratio is 24.44. In terms of profitability, BBNX's ROE is -0.27%, compared to HAE's ROE of +0.12%. Regarding short-term risk, BBNX is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check HAE's competition here
LivaNova PLC (NASDAQ: LIVN)
BBNX vs LIVN Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, LIVN has a market cap of 5B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while LIVN trades at $91.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas LIVN's P/E ratio is 21.65. In terms of profitability, BBNX's ROE is -0.27%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, BBNX is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check LIVN's competition here
Inari Medical, Inc. (NASDAQ: NARI)
BBNX vs NARI Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas NARI's P/E ratio is -59.24. In terms of profitability, BBNX's ROE is -0.27%, compared to NARI's ROE of -0.00%. Regarding short-term risk, BBNX is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
BBNX vs ITGR Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while ITGR trades at $126.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas ITGR's P/E ratio is 19.94. In terms of profitability, BBNX's ROE is -0.27%, compared to ITGR's ROE of +0.06%. Regarding short-term risk, BBNX is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check ITGR's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
BBNX vs TMDX Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, TMDX has a market cap of 3.2B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while TMDX trades at $90.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas TMDX's P/E ratio is 46.16. In terms of profitability, BBNX's ROE is -0.27%, compared to TMDX's ROE of +0.28%. Regarding short-term risk, BBNX is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
BBNX vs AXGN Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, AXGN has a market cap of 3B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while AXGN trades at $50.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas AXGN's P/E ratio is 133.92. In terms of profitability, BBNX's ROE is -0.27%, compared to AXGN's ROE of -0.11%. Regarding short-term risk, BBNX is more volatile compared to AXGN. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check AXGN's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
BBNX vs IRTC Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, IRTC has a market cap of 2.8B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while IRTC trades at $86.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas IRTC's P/E ratio is -200.14. In terms of profitability, BBNX's ROE is -0.27%, compared to IRTC's ROE of -0.23%. Regarding short-term risk, BBNX is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check IRTC's competition here
Neogen Corporation (NASDAQ: NEOG)
BBNX vs NEOG Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, NEOG has a market cap of 2.6B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while NEOG trades at $11.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas NEOG's P/E ratio is 41.75. In terms of profitability, BBNX's ROE is -0.27%, compared to NEOG's ROE of -0.03%. Regarding short-term risk, BBNX is more volatile compared to NEOG. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check NEOG's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
BBNX vs UFPT Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, UFPT has a market cap of 2.4B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while UFPT trades at $314.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas UFPT's P/E ratio is 32.08. In terms of profitability, BBNX's ROE is -0.27%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, BBNX is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check UFPT's competition here
NuVasive, Inc. (NASDAQ: NUVA)
BBNX vs NUVA Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas NUVA's P/E ratio is 75.00. In terms of profitability, BBNX's ROE is -0.27%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, BBNX is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check NUVA's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
BBNX vs ESTA Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, ESTA has a market cap of 2B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while ESTA trades at $67.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas ESTA's P/E ratio is -53.36. In terms of profitability, BBNX's ROE is -0.27%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, BBNX is more volatile compared to ESTA. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check ESTA's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
BBNX vs INSP Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, INSP has a market cap of 1.8B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while INSP trades at $62.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas INSP's P/E ratio is 27.46. In terms of profitability, BBNX's ROE is -0.27%, compared to INSP's ROE of +0.12%. Regarding short-term risk, BBNX is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check INSP's competition here
Butterfly Network, Inc. (NYSE: BFLY)
BBNX vs BFLY Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, BFLY has a market cap of 1.7B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while BFLY trades at $6.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas BFLY's P/E ratio is -27.08. In terms of profitability, BBNX's ROE is -0.27%, compared to BFLY's ROE of -0.28%. Regarding short-term risk, BBNX is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check BFLY's competition here
Enovis Corporation (NYSE: ENOV)
BBNX vs ENOV Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, ENOV has a market cap of 1.6B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while ENOV trades at $28.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas ENOV's P/E ratio is 8.08. In terms of profitability, BBNX's ROE is -0.27%, compared to ENOV's ROE of -0.36%. Regarding short-term risk, BBNX is more volatile compared to ENOV. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check ENOV's competition here
CONMED Corporation (NYSE: CNMD)
BBNX vs CNMD Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while CNMD trades at $51.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas CNMD's P/E ratio is 11.25. In terms of profitability, BBNX's ROE is -0.27%, compared to CNMD's ROE of +0.07%. Regarding short-term risk, BBNX is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check CNMD's competition here
Novocure Ltd (NASDAQ: NVCR)
BBNX vs NVCR Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, NVCR has a market cap of 1.4B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while NVCR trades at $11.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas NVCR's P/E ratio is -11.14. In terms of profitability, BBNX's ROE is -0.27%, compared to NVCR's ROE of -0.36%. Regarding short-term risk, BBNX is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check NVCR's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
BBNX vs LMRI Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, LMRI has a market cap of 1.3B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while LMRI trades at $13.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas LMRI's P/E ratio is -27.08. In terms of profitability, BBNX's ROE is -0.27%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, BBNX is more volatile compared to LMRI. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check LMRI's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
BBNX vs PRCT Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, PRCT has a market cap of 1.3B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while PRCT trades at $23.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas PRCT's P/E ratio is -11.88. In terms of profitability, BBNX's ROE is -0.27%, compared to PRCT's ROE of -0.33%. Regarding short-term risk, BBNX is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check PRCT's competition here
Heska Corporation (NASDAQ: HSKA)
BBNX vs HSKA Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas HSKA's P/E ratio is -62.49. In terms of profitability, BBNX's ROE is -0.27%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, BBNX is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check HSKA's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
BBNX vs TNDM Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while TNDM trades at $18.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas TNDM's P/E ratio is -20.12. In terms of profitability, BBNX's ROE is -0.27%, compared to TNDM's ROE of -0.36%. Regarding short-term risk, BBNX is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check TNDM's competition here
Avanos Medical, Inc. (NYSE: AVNS)
BBNX vs AVNS Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas AVNS's P/E ratio is 27.77. In terms of profitability, BBNX's ROE is -0.27%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, BBNX is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check AVNS's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
BBNX vs IART Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, IART has a market cap of 1.1B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while IART trades at $14.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas IART's P/E ratio is 6.16. In terms of profitability, BBNX's ROE is -0.27%, compared to IART's ROE of +0.01%. Regarding short-term risk, BBNX is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check IART's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
BBNX vs SIBN Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, SIBN has a market cap of 1.1B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while SIBN trades at $25.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas SIBN's P/E ratio is -73.82. In terms of profitability, BBNX's ROE is -0.27%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, BBNX is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check SIBN's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
BBNX vs SILK Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas SILK's P/E ratio is -18.96. In terms of profitability, BBNX's ROE is -0.27%, compared to SILK's ROE of -0.35%. Regarding short-term risk, BBNX is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check SILK's competition here
IRadimed Corporation (NASDAQ: IRMD)
BBNX vs IRMD Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while IRMD trades at $86.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas IRMD's P/E ratio is 43.58. In terms of profitability, BBNX's ROE is -0.27%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, BBNX is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check IRMD's competition here
Paragon 28, Inc. (NYSE: FNA)
BBNX vs FNA Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas FNA's P/E ratio is -19.83. In terms of profitability, BBNX's ROE is -0.27%, compared to FNA's ROE of -0.35%. Regarding short-term risk, BBNX is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check FNA's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
BBNX vs ATEC Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, ATEC has a market cap of 1.1B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while ATEC trades at $7.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas ATEC's P/E ratio is -12.45. In terms of profitability, BBNX's ROE is -0.27%, compared to ATEC's ROE of -5.47%. Regarding short-term risk, BBNX is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check ATEC's competition here
CeriBell, Inc. (NASDAQ: CBLL)
BBNX vs CBLL Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, CBLL has a market cap of 1.1B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while CBLL trades at $27.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas CBLL's P/E ratio is -15.61. In terms of profitability, BBNX's ROE is -0.27%, compared to CBLL's ROE of -0.55%. Regarding short-term risk, BBNX is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check CBLL's competition here
Artivion, Inc. (NYSE: AORT)
BBNX vs AORT Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, AORT has a market cap of 1B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while AORT trades at $20.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas AORT's P/E ratio is 34.38. In terms of profitability, BBNX's ROE is -0.27%, compared to AORT's ROE of -0.04%. Regarding short-term risk, BBNX is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check AORT's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
BBNX vs AHCO Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, AHCO has a market cap of 1B. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while AHCO trades at $7.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas AHCO's P/E ratio is 14.99. In terms of profitability, BBNX's ROE is -0.27%, compared to AHCO's ROE of -0.29%. Regarding short-term risk, BBNX is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check AHCO's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
BBNX vs KIDS Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, KIDS has a market cap of 874.2M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while KIDS trades at $33.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas KIDS's P/E ratio is -24.99. In terms of profitability, BBNX's ROE is -0.27%, compared to KIDS's ROE of -0.10%. Regarding short-term risk, BBNX is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check KIDS's competition here
Picard Medical, Inc. (AMEX: PMI)
BBNX vs PMI Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, PMI has a market cap of 850.6M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while PMI trades at $8.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas PMI's P/E ratio is -6.90. In terms of profitability, BBNX's ROE is -0.27%, compared to PMI's ROE of -9.31%. Regarding short-term risk, BBNX is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check PMI's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
BBNX vs CSII Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas CSII's P/E ratio is -20.83. In terms of profitability, BBNX's ROE is -0.27%, compared to CSII's ROE of -0.14%. Regarding short-term risk, BBNX is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check CSII's competition here
Varex Imaging Corporation (NASDAQ: VREX)
BBNX vs VREX Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, VREX has a market cap of 783.4M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while VREX trades at $18.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas VREX's P/E ratio is 19.42. In terms of profitability, BBNX's ROE is -0.27%, compared to VREX's ROE of +0.05%. Regarding short-term risk, BBNX is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check VREX's competition here
Bioventus Inc. (NASDAQ: BVS)
BBNX vs BVS Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, BVS has a market cap of 765.5M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while BVS trades at $11.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas BVS's P/E ratio is 14.71. In terms of profitability, BBNX's ROE is -0.27%, compared to BVS's ROE of +0.27%. Regarding short-term risk, BBNX is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check BVS's competition here
InMode Ltd. (NASDAQ: INMD)
BBNX vs INMD Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, INMD has a market cap of 763.3M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while INMD trades at $13.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas INMD's P/E ratio is 9.21. In terms of profitability, BBNX's ROE is -0.27%, compared to INMD's ROE of +0.12%. Regarding short-term risk, BBNX is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check INMD's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
BBNX vs CTKB Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, CTKB has a market cap of 757.2M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while CTKB trades at $5.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas CTKB's P/E ratio is -30.67. In terms of profitability, BBNX's ROE is -0.27%, compared to CTKB's ROE of -0.25%. Regarding short-term risk, BBNX is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check CTKB's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
BBNX vs DCTH Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, DCTH has a market cap of 697.4M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while DCTH trades at $20.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas DCTH's P/E ratio is 2010.00. In terms of profitability, BBNX's ROE is -0.27%, compared to DCTH's ROE of +0.06%. Regarding short-term risk, BBNX is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check DCTH's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
BBNX vs PACB Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, PACB has a market cap of 696.3M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while PACB trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas PACB's P/E ratio is -5.46. In terms of profitability, BBNX's ROE is -0.27%, compared to PACB's ROE of +6.04%. Regarding short-term risk, BBNX is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check PACB's competition here
Surmodics, Inc. (NASDAQ: SRDX)
BBNX vs SRDX Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas SRDX's P/E ratio is -34.66. In terms of profitability, BBNX's ROE is -0.27%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, BBNX is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check SRDX's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
BBNX vs SGHT Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, SGHT has a market cap of 597.5M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while SGHT trades at $10.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas SGHT's P/E ratio is -19.20. In terms of profitability, BBNX's ROE is -0.27%, compared to SGHT's ROE of -0.52%. Regarding short-term risk, BBNX is more volatile compared to SGHT. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check SGHT's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
BBNX vs TCMD Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, TCMD has a market cap of 596.3M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while TCMD trades at $26.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas TCMD's P/E ratio is 24.65. In terms of profitability, BBNX's ROE is -0.27%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, BBNX is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check TCMD's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
BBNX vs APEN Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas APEN's P/E ratio is -9.43. In terms of profitability, BBNX's ROE is -0.27%, compared to APEN's ROE of -0.85%. Regarding short-term risk, BBNX is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check APEN's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
BBNX vs AVR Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, AVR has a market cap of 574M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while AVR trades at $5.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas AVR's P/E ratio is -3.04. In terms of profitability, BBNX's ROE is -0.27%, compared to AVR's ROE of -0.78%. Regarding short-term risk, BBNX is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check AVR's competition here
ZimVie Inc. (NASDAQ: ZIMV)
BBNX vs ZIMV Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, BBNX's ROE is -0.27%, compared to ZIMV's ROE of -0.07%. Regarding short-term risk, BBNX is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check ZIMV's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
BBNX vs SENS Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, SENS has a market cap of 530.3M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while SENS trades at $10.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas SENS's P/E ratio is -4.50. In terms of profitability, BBNX's ROE is -0.27%, compared to SENS's ROE of -1.86%. Regarding short-term risk, BBNX is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check SENS's competition here
Avita Medical Inc. (NASDAQ: RCEL)
BBNX vs RCEL Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, RCEL has a market cap of 438.5M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while RCEL trades at $17.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas RCEL's P/E ratio is -12.26. In terms of profitability, BBNX's ROE is -0.27%, compared to RCEL's ROE of +1.46%. Regarding short-term risk, BBNX is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check RCEL's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
BBNX vs NPCE Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, NPCE has a market cap of 435.6M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while NPCE trades at $12.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas NPCE's P/E ratio is -22.26. In terms of profitability, BBNX's ROE is -0.27%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, BBNX is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check NPCE's competition here
Cerus Corporation (NASDAQ: CERS)
BBNX vs CERS Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, CERS has a market cap of 393.8M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while CERS trades at $1.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas CERS's P/E ratio is -64.78. In terms of profitability, BBNX's ROE is -0.27%, compared to CERS's ROE of -0.11%. Regarding short-term risk, BBNX is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check CERS's competition here
CapsoVision, Inc. (NASDAQ: CV)
BBNX vs CV Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, CV has a market cap of 338.9M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while CV trades at $6.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas CV's P/E ratio is -10.11. In terms of profitability, BBNX's ROE is -0.27%, compared to CV's ROE of -1.78%. Regarding short-term risk, BBNX is more volatile compared to CV. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check CV's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
BBNX vs SSII Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, SSII has a market cap of 322.8M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while SSII trades at $1.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas SSII's P/E ratio is -26.83. In terms of profitability, BBNX's ROE is -0.27%, compared to SSII's ROE of -0.27%. Regarding short-term risk, BBNX is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check SSII's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
BBNX vs TMCI Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, TMCI has a market cap of 317.4M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while TMCI trades at $4.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas TMCI's P/E ratio is -5.19. In terms of profitability, BBNX's ROE is -0.27%, compared to TMCI's ROE of -0.76%. Regarding short-term risk, BBNX is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check TMCI's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
BBNX vs SMLR Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas SMLR's P/E ratio is 3.92. In terms of profitability, BBNX's ROE is -0.27%, compared to SMLR's ROE of +0.20%. Regarding short-term risk, BBNX is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check SMLR's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
BBNX vs INFU Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, INFU has a market cap of 304.1M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while INFU trades at $15.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas INFU's P/E ratio is 37.24. In terms of profitability, BBNX's ROE is -0.27%, compared to INFU's ROE of +0.16%. Regarding short-term risk, BBNX is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check INFU's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
BBNX vs OFIX Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, OFIX has a market cap of 290M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while OFIX trades at $7.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas OFIX's P/E ratio is -4.64. In terms of profitability, BBNX's ROE is -0.27%, compared to OFIX's ROE of -0.10%. Regarding short-term risk, BBNX is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check OFIX's competition here
Profound Medical Corp. (NASDAQ: PROF)
BBNX vs PROF Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, PROF has a market cap of 281.3M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while PROF trades at $7.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas PROF's P/E ratio is -7.84. In terms of profitability, BBNX's ROE is -0.27%, compared to PROF's ROE of -0.31%. Regarding short-term risk, BBNX is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check PROF's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
BBNX vs CLPT Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, CLPT has a market cap of 281.1M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while CLPT trades at $8.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas CLPT's P/E ratio is -7.43. In terms of profitability, BBNX's ROE is -0.27%, compared to CLPT's ROE of -1.70%. Regarding short-term risk, BBNX is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check CLPT's competition here
Quantum-Si incorporated (NASDAQ: QSI)
BBNX vs QSI Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, QSI has a market cap of 254.7M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while QSI trades at $1.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas QSI's P/E ratio is -2.78. In terms of profitability, BBNX's ROE is -0.27%, compared to QSI's ROE of -0.45%. Regarding short-term risk, BBNX is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check QSI's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
BBNX vs MGRM Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas MGRM's P/E ratio is -12.00. In terms of profitability, BBNX's ROE is -0.27%, compared to MGRM's ROE of -1.17%. Regarding short-term risk, BBNX is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check MGRM's competition here
Electromed, Inc. (AMEX: ELMD)
BBNX vs ELMD Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, ELMD has a market cap of 226.6M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while ELMD trades at $27.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas ELMD's P/E ratio is 20.87. In terms of profitability, BBNX's ROE is -0.27%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, BBNX is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check ELMD's competition here
Nevro Corp. (NYSE: NVRO)
BBNX vs NVRO Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas NVRO's P/E ratio is -1.91. In terms of profitability, BBNX's ROE is -0.27%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, BBNX is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check NVRO's competition here
RxSight, Inc. (NASDAQ: RXST)
BBNX vs RXST Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, RXST has a market cap of 205.5M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while RXST trades at $4.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas RXST's P/E ratio is -4.34. In terms of profitability, BBNX's ROE is -0.27%, compared to RXST's ROE of -0.20%. Regarding short-term risk, BBNX is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check RXST's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
BBNX vs BSGM Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas BSGM's P/E ratio is -5.81. In terms of profitability, BBNX's ROE is -0.27%, compared to BSGM's ROE of +6.96%. Regarding short-term risk, BBNX is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check BSGM's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
BBNX vs MDGS Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas MDGS's P/E ratio is -0.27. In terms of profitability, BBNX's ROE is -0.27%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, BBNX is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check MDGS's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
BBNX vs TLSI Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, TLSI has a market cap of 175.5M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while TLSI trades at $2.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas TLSI's P/E ratio is -1.70. In terms of profitability, BBNX's ROE is -0.27%, compared to TLSI's ROE of +7.60%. Regarding short-term risk, BBNX is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check TLSI's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
BBNX vs QIPT Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas QIPT's P/E ratio is -15.87. In terms of profitability, BBNX's ROE is -0.27%, compared to QIPT's ROE of -0.08%. Regarding short-term risk, BBNX is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check QIPT's competition here
Inogen, Inc. (NASDAQ: INGN)
BBNX vs INGN Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, INGN has a market cap of 159.2M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while INGN trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas INGN's P/E ratio is -6.59. In terms of profitability, BBNX's ROE is -0.27%, compared to INGN's ROE of -0.20%. Regarding short-term risk, BBNX is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
BBNX vs QTRX Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, QTRX has a market cap of 155.1M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while QTRX trades at $3.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas QTRX's P/E ratio is -1.29. In terms of profitability, BBNX's ROE is -0.27%, compared to QTRX's ROE of -0.43%. Regarding short-term risk, BBNX is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check QTRX's competition here
Neuronetics, Inc. (NASDAQ: STIM)
BBNX vs STIM Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, STIM has a market cap of 153.2M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while STIM trades at $2.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas STIM's P/E ratio is -4.57. In terms of profitability, BBNX's ROE is -0.27%, compared to STIM's ROE of -1.28%. Regarding short-term risk, BBNX is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check STIM's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
BBNX vs FOCL Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, FOCL has a market cap of 131.2M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while FOCL trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas FOCL's P/E ratio is -3.38. In terms of profitability, BBNX's ROE is -0.27%, compared to FOCL's ROE of -2.41%. Regarding short-term risk, BBNX is more volatile compared to FOCL. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check FOCL's competition here
Owlet, Inc. (NYSE: OWLT)
BBNX vs OWLT Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, OWLT has a market cap of 127.1M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while OWLT trades at $4.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas OWLT's P/E ratio is -31.07. In terms of profitability, BBNX's ROE is -0.27%, compared to OWLT's ROE of -0.50%. Regarding short-term risk, BBNX is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check OWLT's competition here
Pulmonx Corporation (NASDAQ: LUNG)
BBNX vs LUNG Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, LUNG has a market cap of 121.9M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while LUNG trades at $2.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas LUNG's P/E ratio is -2.77. In terms of profitability, BBNX's ROE is -0.27%, compared to LUNG's ROE of -0.98%. Regarding short-term risk, BBNX is less volatile compared to LUNG. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check LUNG's competition here
iCAD, Inc. (NASDAQ: ICAD)
BBNX vs ICAD Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas ICAD's P/E ratio is -20.37. In terms of profitability, BBNX's ROE is -0.27%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, BBNX is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check ICAD's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
BBNX vs HJLI Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas HJLI's P/E ratio is N/A. In terms of profitability, BBNX's ROE is -0.27%, compared to HJLI's ROE of -0.70%. Regarding short-term risk, BBNX is more volatile compared to HJLI. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check HJLI's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
BBNX vs ASXC Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas ASXC's P/E ratio is -1.12. In terms of profitability, BBNX's ROE is -0.27%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, BBNX is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for BBNX.Check ASXC's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
BBNX vs CATX Comparison November 2026
Beta Bionics, Inc. (NASDAQ: BBNX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BBNX stands at 743.2M. In comparison, CATX has a market cap of 90M. Regarding current trading prices, BBNX is priced at $16.52 on the NASDAQ, while CATX trades at $0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BBNX currently has a P/E ratio of -8.98, whereas CATX's P/E ratio is -0.59. In terms of profitability, BBNX's ROE is -0.27%, compared to CATX's ROE of -0.42%. Regarding short-term risk, BBNX is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for BBNX.Check CATX's competition here